The definitions in this section apply throughout this chapter unless the context clearly requires otherwise.
(1) "Authority" means the health care authority.(2) "Biological product" has the same meaning as in 42 U.S.C. Sec. 262(i)(1).(3) "Biosimilar" has the same meaning as in 42 U.S.C. Sec. 262(i)(2).(4) "Board" means the prescription drug affordability board.(5) "Excess costs" means: (a) Costs of appropriate utilization of a prescription drug that exceed the therapeutic benefit relative to other alternative treatments; or(b) Costs of appropriate utilization of a prescription drug that are not sustainable to public and private health care systems over a 10-year time frame.(6) "Generic drug" has the same meaning as in RCW 69.48.020.(7) "Health carrier" or "carrier" has the same meaning as in RCW 48.43.005.(8) "Manufacturer" means a person, corporation, or other entity engaged in the manufacture of prescription drugs sold in or into Washington state. "Manufacturer" does not include a private label distributor or retail pharmacy that sells a drug under the retail pharmacy's store, or a prescription drug repackager.(9) "Prescription drug" means a drug regulated under chapter 69.41 or 69.50 RCW, including generic, brand name, specialty drugs, and biological products.Added by 2022 c 153,§ 1, eff. 6/9/2022.